Clinical hemolytic disease of newborns is mostly seen in hemolytic disease caused by ABO blood group incompatibility and Rh blood group incompatibility, which will cause jaundice, edema, and even hepatosplenomegaly, and bilirubin encephalopathy as a complication. Treatment of hemolytic disease of the newborn is divided into prenatal treatment and postnatal treatment, as follows: First, prenatal treatment: prenatal treatment should be delivered in advance, plasma exchange in the uterus, intrauterine blood transfusion as well as intrauterine human immunoglobulin to inhibit hemolysis, and there can be oral hepatic enzyme inducer, which can ensure the safety of the uterus. Second, postnatal treatment includes: 1, blue light treatment: diagnosed as hemolytic disease of the newborn after birth, jaundiced children with blue light to treat jaundice, i.e., the use of blue light 425-475nm wavelength, the free bilirubin will be broken down into bound bilirubin, and then discharged through the urine and stools; 2, medication: including phenobarbital class of hepatic enzyme inducer can promote the liver’s enzyme metabolism, the generation of hepatic enzymes, synthesis and metabolism of bilirubin; the role of human immunity to bilirubin. Bilirubin; human immunoglobulin can inhibit hemolytic reaction, which is a kind of immune treatment; in addition, the purpose of human albumin is to make free bilirubin form bound bilirubin to be excreted through urine and stools, and to reduce the amount of unconjugated bilirubin, i.e., the amount of free bilirubin entering into the brain; 3, blood exchange treatment: the degree of jaundice is particularly heavy to reach the indication of blood exchange, and it is necessary to do the blood exchange treatment, which serves to fasten the free bilirubin antibodies and fatal bilirubin antibodies in blood. The function is to quickly change out the free bilirubin antibodies and fatal red blood cells in the blood, reduce hemolysis and prevent the occurrence of bilirubin encephalopathy.